278 related articles for article (PubMed ID: 23324344)
1. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.
Chefetz I; Alvero AB; Holmberg JC; Lebowitz N; Craveiro V; Yang-Hartwich Y; Yin G; Squillace L; Gurrea Soteras M; Aldo P; Mor G
Cell Cycle; 2013 Feb; 12(3):511-21. PubMed ID: 23324344
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G
Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249
[TBL] [Abstract][Full Text] [Related]
3. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
4. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL
Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076
[TBL] [Abstract][Full Text] [Related]
5. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.
Alvero AB; Chen R; Fu HH; Montagna M; Schwartz PE; Rutherford T; Silasi DA; Steffensen KD; Waldstrom M; Visintin I; Mor G
Cell Cycle; 2009 Jan; 8(1):158-66. PubMed ID: 19158483
[TBL] [Abstract][Full Text] [Related]
6. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
8. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
[TBL] [Abstract][Full Text] [Related]
9. Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway.
Zhang Z; Zhu Y; Lai Y; Wu X; Feng Z; Yu Y; Bast RC; Wan X; Xi X; Feng Y
Int J Oncol; 2013 Oct; 43(4):1194-204. PubMed ID: 23921511
[TBL] [Abstract][Full Text] [Related]
10. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF
Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
Bourguignon LY; Wong G; Earle C; Chen L
J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
[TBL] [Abstract][Full Text] [Related]
12. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.
Wang D; Xiang T; Zhao Z; Lin K; Yin P; Jiang L; Liang Z; Zhu B
Oncotarget; 2016 Nov; 7(46):76006-76020. PubMed ID: 27738346
[TBL] [Abstract][Full Text] [Related]
13. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors.
Alvero AB; Montagna MK; Sumi NJ; Joo WD; Graham E; Mor G
Oncotarget; 2014 Sep; 5(18):8703-15. PubMed ID: 25237928
[TBL] [Abstract][Full Text] [Related]
14. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential.
Yin G; Alvero AB; Craveiro V; Holmberg JC; Fu HH; Montagna MK; Yang Y; Chefetz-Menaker I; Nuti S; Rossi M; Silasi DA; Rutherford T; Mor G
Oncogene; 2013 Jan; 32(1):39-49. PubMed ID: 22349827
[TBL] [Abstract][Full Text] [Related]
15. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Casagrande F; Cocco E; Bellone S; Richter CE; Bellone M; Todeschini P; Siegel E; Varughese J; Arin-Silasi D; Azodi M; Rutherford TJ; Pecorelli S; Schwartz PE; Santin AD
Cancer; 2011 Dec; 117(24):5519-28. PubMed ID: 21692061
[TBL] [Abstract][Full Text] [Related]
16. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
[TBL] [Abstract][Full Text] [Related]
17. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.
Liu M; Mor G; Cheng H; Xiang X; Hui P; Rutherford T; Yin G; Rimm DL; Holmberg J; Alvero A; Silasi DA
Reprod Sci; 2013 May; 20(5):605-15. PubMed ID: 23171677
[TBL] [Abstract][Full Text] [Related]
18. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
19. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
20. Adipocyte microenvironment promotes Bcl
Cardenas C; Montagna MK; Pitruzzello M; Lima E; Mor G; Alvero AB
Apoptosis; 2017 Apr; 22(4):558-569. PubMed ID: 28012060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
